Taubman Emerging Scholar Johann Gudjonsson, M.D., Ph.D., receives prestigious research grant

Johann Gudjonsson, M.D., Ph.D., a Taubman Emerging Scholar and assistant professor of dermatology at the University of Michigan Medical school, is among 16 physician-scientists nationwide chosen to receive a prestigious research grant from the Doris Duke Charitable Foundation.

Dr. Gudjonsson will receive $486,000 over three years to continue his study of risk factors for psoriasis.  The Doris Duke foundation grants align with the mission of the Taubman Institute's Emerging Scholars Program, which aims to encourage junior faculty to pursue research into new thrapies and cures in addition to clinical practice.

The Clinical Scientist Development Award (CSDA) provides funding for physician-scientists in the process of establishing their own research teams and enables them to secure 75 percent of their professional time for clinical research, the foundation said.  This year’s awardees are conducting research in diverse areas, including childhood malnutrition, pancreatic cancer and rheumatoid arthritis.

 “For the clinical research workforce to remain strong, we must invest in the next generation of researchers,” said Sindy Escobar-Alvarez, program officer for the Medical Research Program.

“Supporting young physician-scientists as they transition to independence is especially important as they must juggle the responsibilities of conducting research with seeing patients.”

Dr. Gudjonsson approaches the study of psoriasis and other inflammatory diseases at the genetic level, but also contributes to other novel research in the field.  Click here to read about a recent study evaluating the effect of tonsillectomy on psoriasis patients, and why the surgery might help with disease symptoms. 

Two other U-M clinician-scientists, Santhi Ganesh, M.D., and Adam Lauring, M.D., Ph.D., also received the three-year development awards. Click here to read the entire Doris Duke Charitable Foundation press release.

 

 


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift

Connect/
Share/
follow/

Follow Us / Friend Us

Discovery-driven research that matters

phallodin

Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding

 

The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more


Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  

 

Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster

 

video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists